Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  AIDS (London)

• Publication date

  1997-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 9108961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.

  1996cited by this paper
• Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia.

  1996cited by this paper
• Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

  1995cited by this paper
• Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy

  1995cited by this paper
• A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes.

  1994cited by this paper
• Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

  1994cited by this paper
• Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.

  1994cited by this paper
• 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial.

  1993cited by this paper
• Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

  1993cited by this paper

• Antiretroviral (ARV) drug resistance in the developing world.

  2007cites this paper
• Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: a review.

  2003cites this paper
• The prevalence of reduced zidovudine susceptibility in zidovudine‐naive, antiretroviral‐experienced HIV‐1‐infected patients

  2003cites this paper
• Antiretroviral drug resistance among HIV‐1 infected children failing treatment

  2002cites this paper
• Genetic mechanisms of resistance to NRTI and NNRTI

  2002cites this paper
• Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.

  2002cites this paper
• NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.

  2002cites this paper
• ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse Transcriptase

  2002cites this paper
• Effect of introduction of highly active antiretroviral treatment and the changes in patterns of drug-resistant HIV-1 in Japan

  2001cites this paper
• Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV‐1 clinical isolates

  2001cites this paper
• Primary Genotypic and Phenotypic HIV‐1 Drug Resistance in Recent Seroconverters in Madrid

  2001cites this paper
• Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial

  2001cites this paper
• Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.

  2001cites this paper
• The Valine-to-Threonine 75 Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Its Relation with Stavudine Resistance*

  2001cites this paper
• Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.

  2000cites this paper
• COSTS OF OTITIS MEDIA IN A MANAGED CARE POPULATION

  2000cites this paper
• Incidence and impact of resistance against approved antiretroviral drugs

  2000cites this paper
• Emergence of zidovudine resistance in HIV-infected patients receiving stavudine.

  2000cites this paper
• HIV-1 Reverse Transcriptase Mutations Found in a Drug-Experienced Patient Confer Reduced Susceptibility to Multiple Nucleoside Reverse Transcriptase Inhibitors

  2000cites this paper
• Genotypic characterization of human immunodeficiency virus type 1 isolated from vertically infected children with antiretroviral therapy experience.

  2000cites this paper
• Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine

  2000cites this paper
• Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2′-Deoxynucleoside Triphosphates

  2000cites this paper
• A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance

  1999cites this paper
• Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.

  1999cites this paper
• Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.

  1999cites this paper
• Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy

  1999cites this paper
• Stavudine: an update of its use in the treatment of HIV infection.

  1999cites this paper
• Antiretroviral drug resistance in HIV-1

  1999cites this paper
• Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.

  1999cites this paper
• Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral‐experienced patients

  1998cites this paper
• Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy.

  1998cites this paper
• Genotypic and Phenotypic Resistance to Stavudine after Long-Term Monotherapy

  1998cites this paper
• Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: evidence of variabilities in levels of virion-associated RT.

  1998cites this paper
• Comparison of Once and Twice Daily Dosing of Didanosine in Combination with Stavudine for the Treatment of HIV-1 Infection

  1998cites this paper
• [The role of stavudine in antiretroviral therapy].

  1998cites this paper
• Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group.

  1998cites this paper
• [Antiretroviral treatment: when to start and with what?].

  1998cites this paper
• Tratamiento antirretroviral de la infección VIH en la infancia

  1998cites this paper
• Recent advances in antiretroviral therapy and HIV infection monitoring.

  1997cites this paper